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Arterial hypertension is the most common cardiovascular disease. Atrial fibrillation in
hypertension has frequent occurrence, which increases with age. While the mechanism
underlying the development of atrial fibrillation is complex, hypertension is considered one
of the main pathogenic factors resulting in this arrhythmia. Hypertension is also the key
risk factor for stroke, with the risk markedly increasing in the presence of atrial fibrillation.
In addition, hypertension is a major factor when stratifying the risk of thromboembolism in
atrial fibrillation.
Antihypertensive therapy reduces not only the risk for stroke but also the risk for atrial
fibrillation.
Based on current evidence (mostly retrospective data), some classes of antihypertensive
agents seem to be more effective than others in preventing recent-onset atrial fibrillation.
This paper discusses various options of antihypertensive strategy in hypertensive patients
with atrial fibrillation. Anticoagulation and antiarrhythmic therapy make an integral part of
AF management.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Arterial hypertension is the most common cardiovascular
(CV) disease with a high prevalence (20–50%) in the adult
population of industrialized nations [1–3]. Together with
smoking, diabetes, dyslipidemia, and obesity (primarily
abdominal), arterial hypertension is also one of the major
risk factors for stroke, coronary heart disease (CHD), and
peripheral arterial disease. Meta-analyses of population-
based studies have consistently documented an association
between cerebrovascular and CV morbidity and mortality on
the one hand, and blood pressure (BP) levels on the other.
Atrial fibrillation (AF) is the most common arrhythmia whose
occurrence rises steeply with increasing age and is estimated
to be somewhere at 1–2% in the general population. Interest-
ingly, the prevalence of hypertension in studies designed to
investigate various aspects of AF is reported to be 50–90% [4].
Hypertension constitutes one of the leading risk factors when
calculating the annual risk for stroke (CHA2DS2-VASc score).
Left ventricular hypertrophy (LVH) and dilatation have been
shown to be independent risk factors for AF.
Because of the very frequent co-incidence of hypertension
and AF in hypertensive patients, the Task Force ‘‘Hyperten-
sion, arrhythmia, and atrial fibrillation’’ of the European
Society of Hypertension (ESH) decided to develop a position
paper summarizing current concepts of diagnostic, preven-
tive, and therapeutic approaches in hypertension associated
with AF [4]. Our brief paper discusses issues related to
selection of antihypertensive agents in patients with AF
based primarily on the ESH document [4].2. Atrial fibrillation and antihypertensive
therapy
Given the high risk for CV events, and stroke in particular, in
hypertensive patients with AF, achieving normal BP levels is a
most important consideration. Adequate BP control in AF
patients is critical also because of the frequent concomitant
chronic anticoagulation therapy instituted in an effort to
reduce the risk for intracerebral and extracerebral hemor-
rhage with decreasing BP levels.
While antihypertensive agents reduce the risk for AF primar-
ily by decreasing BP per se, there may be other mechanisms
associated with individual classes of antihypertensives such asTable 1 – Treatment of hypertension in AF according to ESH (R
1. The ultimate goal of treatment in hypertensive patients with AF i
2. Renin-angiotensin-aldosterone system blockers reduce the risk fo
high-risk patients, particularly in those with left ventricular dysfu
effects have been documented in post hoc analyses
3. Beta-blockers are effective in heart rate control and, perhaps, also i
their use in preventing recent-onset AF
4. There is a lack of data for the other classes of antihypertensive dLVH or remodeling, an effect on sympathetic nervous activity,
and so on.
Given the scanty evidence from prospective clinical trials,
our choice of antihypertensive therapy can only be based on
data from secondary analyses of large randomized trial and
several meta-analyses. To date, the largest body of data has
been obtained for renin-angiotensin system (RAS) blockers
(see below).
Table 1 lists the main recommendations of the European
Society of Hypertension for the hypertensive patient with AF.2.1. Renin-angiotensin system inhibitors (angiotensin-
converting enzyme inhibitors and angiotensin receptor
blockers)
2.1.1. Results of meta-analyses
As the effect of antihypertensive therapy with RAS blockers
has been assessed in a number of meta-analyses, only the
largest ones are reviewed in the present paper. The main
complication when interpreting results of most studies
included into meta-analyses is that the overwhelming major-
ity of the trials have not been primarily designed to assess
the effect of various CV drug treatments on the risk for AF.
In their meta-analysis of 11 randomized controlled clinical
trials, Healay et al. [5] noted that RAS inhibitors significantly
reduce the relative risk (RR) for recent-onset AF by 28%
(15–40%); however, the benefit had been seen only in
patients with systolic dysfunction or those with LVH. In
another meta-analysis [6], use of angiotensin-converting
enzyme inhibitors (ACEIs) or angiotensin receptor blockers
(sartans, ARBs) was associated with an average 49% (35–72%)
relative reduction in the risk for recent-onset AF, a 53%
(24–92%) decrease in the incidence of failed electrical cardi-
oversion of AF, and with a 61% (20–75%) decrease in the
incidence of recurrent AF after electrical cardioversion.
In yet another meta-analysis by Schneider et al. [7], RAS
inhibition reduced the risk for AF by 32% (0.22–0.43;
po0.00001), with similar effects of ACEIs and ARBs. In
primary prevention, RAS inhibition was the most effective
option in patients with LVH and/or heart failure. In secondary
prevention, RAS inhibition decreased the probability of recur-
rent AF in cardioversion-treated patients by 45% (0.34–0.89;
po0.01) and in those receiving pharmacotherapy by 63%
(0.27–0.49; po0.00001).ef. [4]).
s reduction of BP per se
r recent-onset AF. However, this effect has been shown mainly in
nction, LVH, and in myocardial infarction survivors. Most beneficial
n maintaining sinus rhythm. There is inadequate evidence regarding
rugs
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In the Valsartan Antihypertensive Long-term Use Evaluation
(VALUE) trial, use of valsartan (compared with amlodipine)
was associated with a 16% decrease (po0.0455) in the inci-
dence of at least once documented episode of recent-onset
AF, and decreased the incidence of persistent AF by 32%
(po0.0046) [8]. A similar benefit of sartans in decreasing the
incidence of recent-onset AF was documented in pre-
specified analysis of data from the Losartan Intervention
For Endpoint reduction in hypertension (LIFE) trial comparing
the incidence of recent-onset AF in losartan-treated patients
and those treated with the beta-blocker atenolol [9]. In the
ONgoing Telmisartan Alone and in combination with Rami-
pril Global Endpoint Trial (ONTARGET) [10], the incidence
of recent-onset AF was only slightly lower in the group
of patients receiving a sartan (telmisartan) than in those treated
with an ACEI (ramipril) suggesting there is no difference—in
this respect—between the two types of RAS inhibition.
No significant differences in modulating the risk for devel-
oping AF between the RAS inhibitors and placebo were
observed in the TRANSCEND (Telmisartan Randomised
AssessmeNt Study in ACE-INtolerant Subjects with Cardio-
vascular Disease), PROFESS (Prevention Regimen For Effec-
tively avoiding Second Strokes), and HOPE (Heart Outcomes
Prevention Evaluation) trials [11,12].
The recently published double-blind, placebo-controlled
Candesartan in the Prevention of Relapsing Atrial Fibrillation
(CAPRAF) trial did not demonstrate any benefit of candesar-
tan therapy in maintaining sinus rhythm after cardioversion
in patients not treated with antiarrhythmics [13]. Similar
conclusions were reported by the largest secondary preven-
tion GISSI-AF (Gruppo Italiano per lo Studio della Sopravvi-
venza nell’Insufficienza cardiaca atrial fibrillation) trial
involving 1442 patients with CV risk factors (primarily hyper-
tension, in 85%) and paroxysmal or persistent AF after a
recent cardioversion [14]. At one year, no effect on time to the
first recurrent episode of AF as the primary endpoint was
observed after the addition of valsartan to optimal pharma-
cotherapy (including antiarrhythmics). Likewise, no differ-
ences were seen in the numbers of patients experiencing
more than one recurrent episode of AF (26.9% vs. 27.9%)
compared with placebo [14].
Although the outcomes of individual trials and meta-
analyses assessing the effects of RAS blockers on AF preven-
tion are inconsistent, current ESH guidelines do prefer these
classes of antihypertensives for long-term use in this indica-
tion. The effect of RAS blockers seems to be the most marked
in individuals at high CV risk. For example, in the TRAndo-
lapril Cardiac Evaluation (TRACE) trial, long-term trandolapril
use in patients with heart failure resulted in a 55% reduction
of the risk for AF compared with placebo [15].
The beneficial effects of RAS blockers on reducing the risk
for AF can be partly explained by prevention of atrial
remodeling and reversal of LVH [9,16].
2.2. Beta-blockers
Beta-blockers are effective in heart rate control. In heart
failure patients, use of beta-blockers helps maintain sinus
rhythm [17].In the LIFE trial, therapy based on the ARB losartan proved
to be superior to beta-blocker therapy with atenolol in
reducing the risk for recent-onset AF or its recurrence.
However, it is difficult to draw any authoritative conclusions
based on the results of trials comparing two or more regi-
mens of active antihypertensive therapy as it is not clear
whether the observed effects indicate an adverse effect of
one of the regimens or a beneficial effect of the other. The
United Kingdom-based General Practice Research Database
trial including records of an approx. 5 million patients
showed ACEIs, ARBs, and beta-blockers to be superior to
calcium-channel blockers in reducing the risk for AF [18].
Putative modes of action of beta-blockers in this context may
include prevention of adverse remodeling and ischemia or a
decrease in sympathetic tone.
2.3. Calcium-channel blockers (CCBs)
Calcium-channel blockers are a heterogeneous class of drugs
with antihypertensive properties. Non-dihydropyridines such
as diltiazem, and particularly verapamil, lead to delayed
ventricular response to AF. As a result, verapamil may be
effective in heart rate control in AF. As demonstrated by De
Simone et al. [19], verapamil in combination with propafe-
none may significantly decrease the incidence of recurrent AF
as compared with propafenone alone. In another study
involving patients with permanent AF following electrical
cardioversion, verapamil without additional antiarrhythmic
therapy failed to provide a clear benefit [20]. By contrast, long-
term verapamil use in patients with recurrent paroxysms of
AF resulted in a significant decrease in the incidence
of episodes of this arrhythmia [21]. An advantage of verapa-
mil in hypertension and AF, unlike dihydropyridine CCBs,
may be its potential inhibitory effect on sympathetic nervous
activity [22].
By contrast, in the VALUE trial, dihydropyridine CCBs
(amlodipine) were shown to be inferior to valsartan in
preventing AF [8]. Compared with verapamil, dihydropyridine
CCBs thus seem to be less effective in preventing AF.
Retrospective data not distinguishing between dihydropyr-
idine CCBs and verapamil from the US national integrated
database of medical care and pharmaceutical services showed
a lower incidence of recent-onset AF in ACEI-treated patients
as compared with CCB-treated ones [23].
2.4. Diuretics
The ability of diuretics to prevent AF in hypertension has not
been assessed in detail to date. Given the risk of hypokale-
mia, utmost caution should be exercised during chronic
antihypertensive therapy based on potassium-non-sparing
diuretics such as thiazides, chlorthalidone, and indapamide
[4], combined with plasma potassium monitoring.
2.5. Aldosterone antagonists
The risk of patients with primary hyperaldosteronism for
developing AF is 12 times that of patients with essential
hypertension [24]. As a result, it is appropriate to consider
this relatively frequent form of secondary hypertension in
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develop AF, particularly in the presence of kalemia below
4.0 mmol/l. The mechanism of the increased risk for AF in
primary aldosteronism seems to be complex with several
contributing factors such as hypokalemia, severe hyperten-
sion or LVH. Patients with AF have been reported to have
increased aldosterone levels [4]. Several trials with spirono-
lactone and eplerenone are currently underway.
2.6. Combination antihypertensive therapy
Combination therapy in hypertension should be used in at
least 70% of individuals with high BP levels. Quite surpris-
ingly, no data are available in this respect.
Potentially appropriate combinations in hypertension and
AF include those of an ACE inhibitor/ARBþa CCB (particularly
a non-dihydropyridine type/verapamil) or an ACE inhibitor/
ARBþa beta-blocker. Use of the latter dual combination may
be questioned given the lower additive antihypertensive
effect of the RAS blocker and beta-blocker combination.
A potentially useful combination in heart failure patients
may be that of an ACE inhibitor/ARBþa diuretic and/or an
ACE inhibitor/ARBþbeta-blocker.3. Conclusion
There is no doubt patients with arterial hypertension are at
increased risk for developing AF. Drug-based strategies in AF
in hypertension should include not only antihypertensive but
also antiarrhythmic and anticoagulant agents. The main
classes of antihypertensives may seem to differ in modulat-
ing the risk for AF. Compared with other antihypertensive
classes, use of ACE inhibitors, angiotensin receptor blockers,
and beta-blockers seems to be more effective in preventing
AF, particularly in high-risk populations (with CHD, chronic
heart failure, left ventricular hypertension, and in myocardial
infarction survivors). Among the other antihypertensives,
verapamil is a potentially suitable alternative. Angiotensin-
converting enzyme inhibitors/ARBs plus CCBs (particularly
non-dihydropyridine type-verapamil) or ACEIs/ARBs and
diuretics may be useful options for combination antihyper-
tensive therapy in AF.
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